2026-01-18 - Analysis Report
**Financial Report for Merck & Co Inc (MRK)**

**Company Overview**: Pharmaceutical company developing and manufacturing a range of medications
**Recent Stock Price Fluctuation**: $108.83 (Current), $109.65 (5-day SMA), $107.19 (20-day SMA), $98.44 (60-day SMA)

**Cumulative Return Comparison**

* Review Stock (Merck & Co Inc): 25.67%
* Comparison Stock (S&P 500, VOO): 93.36%
* Divergence: -68.69%

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 24.0% | 14.7% | 21.0% | 0.7 | 182.1B |
| 2017-2019  | 37.0% | 14.7% | 20.0% | 0.7 | 216.8B |
| 2018-2020  | 13.0% | 19.3% | -8.0% | 0.7 | 195.0B |
| 2019-2021  | 0.0% | 19.3% | -43.0% | 0.6 | 191.4B |
| 2020-2022  | 14.0% | 16.3% | 16.0% | 0.5 | 277.1B |
| 2021-2023  | 31.0% | 14.3% | 30.0% | 0.3 | 272.3B |
| 2022-2024  | -5.0% | 24.9% | -24.0% | 0.3 | 248.5B |
| 2023-2025  | -24.0% | 39.0% | -86.0% | 0.3 | 262.9B |

**Stock Price Trend Indicators**

* RSI: 56.63
* PPO: -0.18
* Market Risk Indicator (MRI): 0.80
* Expected Return (%): -26.70%
* Recent relative divergence change: -0.70 (worsening)
* 7-day Rank change: -58 (rank down)
* 7-day Dynamic Expected Return change: 0.00 (flat)
* Fluctuation Issue: sharp rebound (-1.93)

**Market News and Events**

* [2026-01-17] Merck & Co., Inc. $MRK Shares Sold by QRG Capital Management Inc. - MarketBeat
* [2026-01-15] What’s In Store For Merck Stock? - Trefis
* [2025-12-30] FDA Fast-Tracks Two Merck (MRK) Drugs With Blockbuster Potential - Yahoo Finance
* [2026-01-15] Is Merck Stock A Trap At $110? - Forbes
* [2026-01-16] Merck stock slips as FDA fast-track questions build and earnings near - TechStock²
* [2026-01-16] Is Merck (MRK) Pricing In Its Recent Share Run Or Leaving Further Upside? - simplywall.st

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.90 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 113.48 / 135.00 / 83.00

**Recent Earnings Analysis**

| Date     | EPS  | Revenue   |
|----------|------|------------|
| 2025-11-05 | 2.32 | 17.28 B$  |
| 2025-08-05 | 1.76 | 15.81 B$  |
| 2025-05-02 | 2.01 | 15.53 B$  |
| 2024-11-06 | 1.25 | 16.66 B$  |
| 2025-11-05 | 1.25 | 16.66 B$  |

**Financial Information - Revenue and Profitability**

| Quarter   | Revenue | Profit Margin |
|-----------|---------|---------------|
| 2025-09-30 | 17.28B | 77.69% |
| 2025-06-30 | 15.81B | 77.50% |
| 2025-03-31 | 15.53B | 77.98% |
| 2024-12-31 | 15.62B | 75.50% |
| 2024-09-30 | 16.66B | 75.51% |

**Financial Information - Capital and Profitability**

| Quarter   | Equity | ROE    |
|-----------|---------|--------|
| 2025-09-30 | 51.85B | 11.16% |
| 2025-06-30 | 48.99B | 9.04%  |
| 2025-03-31 | 48.34B | 10.51% |
| 2024-12-31 | 46.31B | 8.08%  |
| 2024-09-30 | 44.50B | 7.09%  |

**Comprehensive Analysis**
Based on the provided data, Merck & Co Inc has experienced fluctuations in its stock price, with a recent sharp decline. The cumulative return analysis shows a significant divergence between the review stock and the comparison stock (S&P 500). The Alpha, Beta analysis indicates varying performance across different periods, with some positive and some negative returns. Market risk indicators suggest a medium-risk investment opportunity. Analyst opinions are generally positive, with a target price of $113.48. Recent earnings analysis shows increasing EPS and revenue. Financial information indicates stable profitability and a significant increase in equity.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.